Summary

The global Short-Acting Nicotine Replacement Therapy Products market is projected to grow from US$ 1810 million in 2025 to US$ 2620 million by 2032, at a CAGR of 5.6% (2026-2032), driven by critical product segments and diverse end‑use applications.
Short-acting nicotine replacement therapy (NRT) products are non-combustible smoking cessation aids designed to rapidly release and deliver nicotine—typically via the oral mucosa or nasal passages—to alleviate sudden cravings and nicotine withdrawal symptoms during the quitting process. Key examples include nicotine gum, lozenges, oral sprays, nasal sprays, and certain fast-release oral formulations. Sold primarily through pharmacies, hospitals, retail outlets, and online platforms, these products are widely used to help smokers quit and reduce tobacco dependence; their market continues to grow alongside the advancement of public health tobacco control policies, rising awareness regarding smoking cessation, and increasing consumer acceptance of over-the-counter smoking cessation aids.
The short-acting nicotine replacement therapy products market is primarily driven by continued implementation of tobacco-control policies, rising motivation among smokers to quit, growing demand for nicotine dependence treatment, and increasing consumer acceptance of convenient smoking cessation aids. Compared with long-acting products such as nicotine patches, short-acting formats including nicotine gum, lozenges, oral sprays, and nasal sprays can provide relatively rapid relief from sudden cravings and withdrawal symptoms, while offering flexible, on-demand dosing. These characteristics make them suitable both as standalone therapies and in combination with long-acting nicotine patches for more comprehensive craving management. At the same time, wider promotion of evidence-based smoking cessation interventions by healthcare providers and public health organizations, expansion of over-the-counter and online pharmacy channels, and growing awareness of the health risks associated with smoking and secondhand smoke are expanding the potential user base. Continued innovation in flavors, dosage forms, nicotine strengths, and portability is also improving treatment adherence and user convenience, further supporting growth of the global short-acting nicotine replacement therapy products market.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Short-Acting Nicotine Replacement Therapy Products market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Kenvue
Perrigo
Dr. Reddy's Laboratories
Haleon
Philip Morris International
Cipla
Rusan Pharma
Glenmark Pharmaceuticals
Piramal Pharma
Rubicon Consumer Healthcare
Alkalon
Sparsha Pharma
TFI India Labs
Nico Orgo Marketing
Lucy Goods
Blip
AdhexPharma
Jones
Segment by Type
Nicotine Gum
Nicotine Lozenges
Nicotine Mouth Spray
Nicotine Nasal Spray
Others
Segment by Dose
Low Dose
Medium Dose
High Dose
Segment by Application
Online Sales
Offline Sales
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Short-Acting Nicotine Replacement Therapy Products study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Short-Acting Nicotine Replacement Therapy Products: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Short-Acting Nicotine Replacement Therapy Products Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Nicotine Gum
1.2.3 Nicotine Lozenges
1.2.4 Nicotine Mouth Spray
1.2.5 Nicotine Nasal Spray
1.2.6 Others
1.3 Market Segmentation by Dose
1.3.1 Global Short-Acting Nicotine Replacement Therapy Products Market Size by Dose, 2021 vs 2025 vs 2032
1.3.2 Low Dose
1.3.3 Medium Dose
1.3.4 High Dose
1.4 Market Segmentation by Application
1.4.1 Global Short-Acting Nicotine Replacement Therapy Products Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Online Sales
1.4.3 Offline Sales
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Short-Acting Nicotine Replacement Therapy Products Revenue Estimates and Forecasts (2021-2032)
2.2 Global Short-Acting Nicotine Replacement Therapy Products Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Short-Acting Nicotine Replacement Therapy Products Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Short-Acting Nicotine Replacement Therapy Products Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Nicotine Gum: Market Share by Key Players
3.3.2 Nicotine Lozenges: Market Share by Key Players
3.3.3 Nicotine Mouth Spray: Market Share by Key Players
3.3.4 Nicotine Nasal Spray: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Short-Acting Nicotine Replacement Therapy Products Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Short-Acting Nicotine Replacement Therapy Products Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Short-Acting Nicotine Replacement Therapy Products Market by Dose
4.2.1 Global Revenue by Dose (2021-2032)
4.2.2 Global Revenue-Based Market Share by Dose (2021-2032)
4.3 Key Product Attributes and Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Short-Acting Nicotine Replacement Therapy Products Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Short-Acting Nicotine Replacement Therapy Products Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Short-Acting Nicotine Replacement Therapy Products Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Short-Acting Nicotine Replacement Therapy Products Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Short-Acting Nicotine Replacement Therapy Products Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Short-Acting Nicotine Replacement Therapy Products Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Short-Acting Nicotine Replacement Therapy Products Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Kenvue
11.1.1 Kenvue Corporation Information
11.1.2 Kenvue Business Overview
11.1.3 Kenvue Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.1.4 Kenvue Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.1.5 Kenvue Short-Acting Nicotine Replacement Therapy Products Revenue by Product in 2025
11.1.6 Kenvue Short-Acting Nicotine Replacement Therapy Products Revenue by Application in 2025
11.1.7 Kenvue Short-Acting Nicotine Replacement Therapy Products Revenue by Geographic Area in 2025
11.1.8 Kenvue Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
11.1.9 Kenvue Recent Developments
11.2 Perrigo
11.2.1 Perrigo Corporation Information
11.2.2 Perrigo Business Overview
11.2.3 Perrigo Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.2.4 Perrigo Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.2.5 Perrigo Short-Acting Nicotine Replacement Therapy Products Revenue by Product in 2025
11.2.6 Perrigo Short-Acting Nicotine Replacement Therapy Products Revenue by Application in 2025
11.2.7 Perrigo Short-Acting Nicotine Replacement Therapy Products Revenue by Geographic Area in 2025
11.2.8 Perrigo Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
11.2.9 Perrigo Recent Developments
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Corporation Information
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.3.4 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.3.5 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products Revenue by Product in 2025
11.3.6 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products Revenue by Application in 2025
11.3.7 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products Revenue by Geographic Area in 2025
11.3.8 Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
11.3.9 Dr. Reddy's Laboratories Recent Developments
11.4 Haleon
11.4.1 Haleon Corporation Information
11.4.2 Haleon Business Overview
11.4.3 Haleon Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.4.4 Haleon Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.4.5 Haleon Short-Acting Nicotine Replacement Therapy Products Revenue by Product in 2025
11.4.6 Haleon Short-Acting Nicotine Replacement Therapy Products Revenue by Application in 2025
11.4.7 Haleon Short-Acting Nicotine Replacement Therapy Products Revenue by Geographic Area in 2025
11.4.8 Haleon Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
11.4.9 Haleon Recent Developments
11.5 Philip Morris International
11.5.1 Philip Morris International Corporation Information
11.5.2 Philip Morris International Business Overview
11.5.3 Philip Morris International Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.5.4 Philip Morris International Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.5.5 Philip Morris International Short-Acting Nicotine Replacement Therapy Products Revenue by Product in 2025
11.5.6 Philip Morris International Short-Acting Nicotine Replacement Therapy Products Revenue by Application in 2025
11.5.7 Philip Morris International Short-Acting Nicotine Replacement Therapy Products Revenue by Geographic Area in 2025
11.5.8 Philip Morris International Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
11.5.9 Philip Morris International Recent Developments
11.6 Cipla
11.6.1 Cipla Corporation Information
11.6.2 Cipla Business Overview
11.6.3 Cipla Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.6.4 Cipla Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.6.5 Cipla Recent Developments
11.7 Rusan Pharma
11.7.1 Rusan Pharma Corporation Information
11.7.2 Rusan Pharma Business Overview
11.7.3 Rusan Pharma Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.7.4 Rusan Pharma Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.7.5 Rusan Pharma Recent Developments
11.8 Glenmark Pharmaceuticals
11.8.1 Glenmark Pharmaceuticals Corporation Information
11.8.2 Glenmark Pharmaceuticals Business Overview
11.8.3 Glenmark Pharmaceuticals Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.8.4 Glenmark Pharmaceuticals Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.8.5 Glenmark Pharmaceuticals Recent Developments
11.9 Piramal Pharma
11.9.1 Piramal Pharma Corporation Information
11.9.2 Piramal Pharma Business Overview
11.9.3 Piramal Pharma Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.9.4 Piramal Pharma Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.9.5 Piramal Pharma Recent Developments
11.10 Rubicon Consumer Healthcare
11.10.1 Rubicon Consumer Healthcare Corporation Information
11.10.2 Rubicon Consumer Healthcare Business Overview
11.10.3 Rubicon Consumer Healthcare Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.10.4 Rubicon Consumer Healthcare Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Alkalon
11.11.1 Alkalon Corporation Information
11.11.2 Alkalon Business Overview
11.11.3 Alkalon Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.11.4 Alkalon Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.11.5 Alkalon Recent Developments
11.12 Sparsha Pharma
11.12.1 Sparsha Pharma Corporation Information
11.12.2 Sparsha Pharma Business Overview
11.12.3 Sparsha Pharma Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.12.4 Sparsha Pharma Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.12.5 Sparsha Pharma Recent Developments
11.13 TFI India Labs
11.13.1 TFI India Labs Corporation Information
11.13.2 TFI India Labs Business Overview
11.13.3 TFI India Labs Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.13.4 TFI India Labs Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.13.5 TFI India Labs Recent Developments
11.14 Nico Orgo Marketing
11.14.1 Nico Orgo Marketing Corporation Information
11.14.2 Nico Orgo Marketing Business Overview
11.14.3 Nico Orgo Marketing Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.14.4 Nico Orgo Marketing Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.14.5 Nico Orgo Marketing Recent Developments
11.15 Lucy Goods
11.15.1 Lucy Goods Corporation Information
11.15.2 Lucy Goods Business Overview
11.15.3 Lucy Goods Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.15.4 Lucy Goods Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.15.5 Lucy Goods Recent Developments
11.16 Blip
11.16.1 Blip Corporation Information
11.16.2 Blip Business Overview
11.16.3 Blip Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.16.4 Blip Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.16.5 Blip Recent Developments
11.17 AdhexPharma
11.17.1 AdhexPharma Corporation Information
11.17.2 AdhexPharma Business Overview
11.17.3 AdhexPharma Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.17.4 AdhexPharma Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.17.5 AdhexPharma Recent Developments
11.18 Jones
11.18.1 Jones Corporation Information
11.18.2 Jones Business Overview
11.18.3 Jones Short-Acting Nicotine Replacement Therapy Products Product Features and Attributes
11.18.4 Jones Short-Acting Nicotine Replacement Therapy Products Revenue and Gross Margin (2021-2026)
11.18.5 Jones Recent Developments
12 Short-Acting Nicotine Replacement Therapy Products Value Chain and Ecosystem Analysis
12.1 Short-Acting Nicotine Replacement Therapy Products Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Short-Acting Nicotine Replacement Therapy Products Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Short-Acting Nicotine Replacement Therapy Products Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Dose, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Region (US$ Million), 2021-2026
Table 6. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Region (US$ Million), 2027-2032
Table 7. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 8. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Players (US$ Million), 2021-2026
Table 9. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share by Players (2021-2026)
Table 10. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 11. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Short-Acting Nicotine Replacement Therapy Products Revenue, 2025
Table 12. Global Short-Acting Nicotine Replacement Therapy Products Average Gross Margin (%) by Player (2021 vs 2025)
Table 13. Global Short-Acting Nicotine Replacement Therapy Products Companies Headquarters
Table 14. Global Short-Acting Nicotine Replacement Therapy Products Market Concentration Ratio (CR5)
Table 15. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 16. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 17. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Type (US$ Million), 2021-2026
Table 18. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Type (US$ Million), 2027-2032
Table 19. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Dose (US$ Million), 2021-2026
Table 20. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Dose (US$ Million), 2027-2032
Table 21. Key Product Attributes and Differentiation
Table 22. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Application (US$ Million), 2021-2026
Table 23. Global Short-Acting Nicotine Replacement Therapy Products Revenue by Application (US$ Million), 2027-2032
Table 24. Short-Acting Nicotine Replacement Therapy Products High-Growth Sectors Demand CAGR (2026-2032)
Table 25. Top Customers by Region
Table 26. Top Customers by Application
Table 27. North America Short-Acting Nicotine Replacement Therapy Products Growth Accelerators and Market Barriers
Table 28. North America Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 29. Europe Short-Acting Nicotine Replacement Therapy Products Growth Accelerators and Market Barriers
Table 30. Europe Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Growth Accelerators and Market Barriers
Table 32. Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Central and South America Short-Acting Nicotine Replacement Therapy Products Investment Opportunities and Key Challenges
Table 34. Central and South America Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 35. Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Investment Opportunities and Key Challenges
Table 36. Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 37. Kenvue Corporation Information
Table 38. Kenvue Description and Major Businesses
Table 39. Kenvue Product Features and Attributes
Table 40. Kenvue Revenue (US$ Million) and Gross Margin (2021-2026)
Table 41. Kenvue Revenue Proportion by Product in 2025
Table 42. Kenvue Revenue Proportion by Application in 2025
Table 43. Kenvue Revenue Proportion by Geographic Area in 2025
Table 44. Kenvue Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
Table 45. Kenvue Recent Developments
Table 46. Perrigo Corporation Information
Table 47. Perrigo Description and Major Businesses
Table 48. Perrigo Product Features and Attributes
Table 49. Perrigo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Perrigo Revenue Proportion by Product in 2025
Table 51. Perrigo Revenue Proportion by Application in 2025
Table 52. Perrigo Revenue Proportion by Geographic Area in 2025
Table 53. Perrigo Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
Table 54. Perrigo Recent Developments
Table 55. Dr. Reddy's Laboratories Corporation Information
Table 56. Dr. Reddy's Laboratories Description and Major Businesses
Table 57. Dr. Reddy's Laboratories Product Features and Attributes
Table 58. Dr. Reddy's Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Dr. Reddy's Laboratories Revenue Proportion by Product in 2025
Table 60. Dr. Reddy's Laboratories Revenue Proportion by Application in 2025
Table 61. Dr. Reddy's Laboratories Revenue Proportion by Geographic Area in 2025
Table 62. Dr. Reddy's Laboratories Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
Table 63. Dr. Reddy's Laboratories Recent Developments
Table 64. Haleon Corporation Information
Table 65. Haleon Description and Major Businesses
Table 66. Haleon Product Features and Attributes
Table 67. Haleon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Haleon Revenue Proportion by Product in 2025
Table 69. Haleon Revenue Proportion by Application in 2025
Table 70. Haleon Revenue Proportion by Geographic Area in 2025
Table 71. Haleon Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
Table 72. Haleon Recent Developments
Table 73. Philip Morris International Corporation Information
Table 74. Philip Morris International Description and Major Businesses
Table 75. Philip Morris International Product Features and Attributes
Table 76. Philip Morris International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Philip Morris International Revenue Proportion by Product in 2025
Table 78. Philip Morris International Revenue Proportion by Application in 2025
Table 79. Philip Morris International Revenue Proportion by Geographic Area in 2025
Table 80. Philip Morris International Short-Acting Nicotine Replacement Therapy Products SWOT Analysis
Table 81. Philip Morris International Recent Developments
Table 82. Cipla Corporation Information
Table 83. Cipla Description and Major Businesses
Table 84. Cipla Product Features and Attributes
Table 85. Cipla Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. Cipla Recent Developments
Table 87. Rusan Pharma Corporation Information
Table 88. Rusan Pharma Description and Major Businesses
Table 89. Rusan Pharma Product Features and Attributes
Table 90. Rusan Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 91. Rusan Pharma Recent Developments
Table 92. Glenmark Pharmaceuticals Corporation Information
Table 93. Glenmark Pharmaceuticals Description and Major Businesses
Table 94. Glenmark Pharmaceuticals Product Features and Attributes
Table 95. Glenmark Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 96. Glenmark Pharmaceuticals Recent Developments
Table 97. Piramal Pharma Corporation Information
Table 98. Piramal Pharma Description and Major Businesses
Table 99. Piramal Pharma Product Features and Attributes
Table 100. Piramal Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 101. Piramal Pharma Recent Developments
Table 102. Rubicon Consumer Healthcare Corporation Information
Table 103. Rubicon Consumer Healthcare Description and Major Businesses
Table 104. Rubicon Consumer Healthcare Product Features and Attributes
Table 105. Rubicon Consumer Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)
Table 106. Rubicon Consumer Healthcare Recent Developments
Table 107. Alkalon Corporation Information
Table 108. Alkalon Description and Major Businesses
Table 109. Alkalon Product Features and Attributes
Table 110. Alkalon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 111. Alkalon Recent Developments
Table 112. Sparsha Pharma Corporation Information
Table 113. Sparsha Pharma Description and Major Businesses
Table 114. Sparsha Pharma Product Features and Attributes
Table 115. Sparsha Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 116. Sparsha Pharma Recent Developments
Table 117. TFI India Labs Corporation Information
Table 118. TFI India Labs Description and Major Businesses
Table 119. TFI India Labs Product Features and Attributes
Table 120. TFI India Labs Revenue (US$ Million) and Gross Margin (2021-2026)
Table 121. TFI India Labs Recent Developments
Table 122. Nico Orgo Marketing Corporation Information
Table 123. Nico Orgo Marketing Description and Major Businesses
Table 124. Nico Orgo Marketing Product Features and Attributes
Table 125. Nico Orgo Marketing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 126. Nico Orgo Marketing Recent Developments
Table 127. Lucy Goods Corporation Information
Table 128. Lucy Goods Description and Major Businesses
Table 129. Lucy Goods Product Features and Attributes
Table 130. Lucy Goods Revenue (US$ Million) and Gross Margin (2021-2026)
Table 131. Lucy Goods Recent Developments
Table 132. Blip Corporation Information
Table 133. Blip Description and Major Businesses
Table 134. Blip Product Features and Attributes
Table 135. Blip Revenue (US$ Million) and Gross Margin (2021-2026)
Table 136. Blip Recent Developments
Table 137. AdhexPharma Corporation Information
Table 138. AdhexPharma Description and Major Businesses
Table 139. AdhexPharma Product Features and Attributes
Table 140. AdhexPharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 141. AdhexPharma Recent Developments
Table 142. Jones Corporation Information
Table 143. Jones Description and Major Businesses
Table 144. Jones Product Features and Attributes
Table 145. Jones Revenue (US$ Million) and Gross Margin (2021-2026)
Table 146. Jones Recent Developments
Table 147. Technologies, Platforms and Infrastructure
Table 148. Distributors List
Table 149. Market Trends and Market Evolution
Table 150. Market Drivers and Opportunities
Table 151. Market Challenges, Risks, and Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources


List of Figures
Figure 1. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Nicotine Gum Product Picture
Figure 3. Nicotine Lozenges Product Picture
Figure 4. Nicotine Mouth Spray Product Picture
Figure 5. Nicotine Nasal Spray Product Picture
Figure 6. Others Product Picture
Figure 7. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Dose, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Low Dose Product Picture
Figure 9. Medium Dose Product Picture
Figure 10. High Dose Product Picture
Figure 11. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Global Short-Acting Nicotine Replacement Therapy Products Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Online Sales
Figure 14. Offline Sales
Figure 15. Short-Acting Nicotine Replacement Therapy Products Report Years Considered
Figure 16. Global Short-Acting Nicotine Replacement Therapy Products Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 18. Global Short-Acting Nicotine Replacement Therapy Products Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 19. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share by Region (2021-2032)
Figure 20. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share Ranking (2025)
Figure 21. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 22. Nicotine Gum Revenue-Based Market Share by Player in 2025
Figure 23. Nicotine Lozenges Revenue-Based Market Share by Player in 2025
Figure 24. Nicotine Mouth Spray Revenue-Based Market Share by Player in 2025
Figure 25. Nicotine Nasal Spray Revenue-Based Market Share by Player in 2025
Figure 26. Others Revenue-Based Market Share by Player in 2025
Figure 27. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share by Type (2021-2032)
Figure 28. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share by Dose (2021-2032)
Figure 29. Global Short-Acting Nicotine Replacement Therapy Products Revenue-Based Market Share by Application (2021-2032)
Figure 30. North America Short-Acting Nicotine Replacement Therapy Products Revenue YoY (US$ Million), 2021-2032
Figure 31. North America Top 5 Players Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) in 2025
Figure 32. North America Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) by Application (2021-2032)
Figure 33. US Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 34. Canada Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 35. Mexico Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 36. Europe Short-Acting Nicotine Replacement Therapy Products Revenue YoY (US$ Million), 2021-2032
Figure 37. Europe Top 5 Players Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) in 2025
Figure 38. Europe Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) by Application (2021-2032)
Figure 39. Germany Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 40. France Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 41. U.K. Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 42. Italy Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 43. Russia Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 44. Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Revenue YoY (US$ Million), 2021-2032
Figure 45. Asia-Pacific Top 8 Players Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) in 2025
Figure 46. Asia-Pacific Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) by Application (2021-2032)
Figure 47. Indonesia Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 48. Japan Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 49. South Korea Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 50. Australia Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 51. India Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 52. Indonesia Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 53. Vietnam Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 54. Malaysia Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 55. Philippines Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 56. Singapore Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 57. Central and South America Short-Acting Nicotine Replacement Therapy Products Revenue YoY (US$ Million), 2021-2032
Figure 58. Central and South America Top 5 Players Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) in 2025
Figure 59. Central and South America Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) by Application (2021-2032)
Figure 60. Brazil Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 61. Argentina Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 62. Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Revenue YoY (US$ Million), 2021-2032
Figure 63. Middle East and Africa Top 5 Players Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) in 2025
Figure 64. Middle East and Africa Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million) by Application (2021-2032)
Figure 65. GCC Countries Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 66. Israel Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 67. Egypt Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 68. South Africa Short-Acting Nicotine Replacement Therapy Products Revenue (US$ Million), 2021-2032
Figure 69. Short-Acting Nicotine Replacement Therapy Products Value Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed